Nichi-Iko Pharmaceutical Co., Ltd. has apologized to shareholders “from the bottom of our heart” after once again taking the axe to its full-year profit guidance, this time conceding that the Japanese firm is braced for losses in the tens of billions of yen due largely to deep-seated supply issues at the company’s key Namerikawa plant in the Toyama prefecture.
The new guidance came as Nichi-Iko reported an ¥8.79bn ($76.6m) core operating loss for the first six months of its...







